Gilead Continues its Diversification Strategy with Acquisition of Calistoga Pharmaceuticals
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 3 (Table of Contents)
Published: 9 Mar-2011
DOI: 10.3833/pdr.v2011.i3.1443 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Calistoga Pharmaceuticals’ delta isoform-selective PI3K (phosphoinositide 3-kinase) inhibitor programmes have caught the attention of Gilead Sciences, which has agreed to acquire the Seattle biotech for US$375 M upfront and up to US$225 M in potential milestone payments...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS